Articles

UPDATE: Judge adds probation to Guidant device plea deal

A Minnesota judge has signed off on a plea agreement that calls for Boston Scientific Corp.'s Guidant unit to pay $296 million for failing to properly disclose changes made to some implantable heart devices, but added three years of probation to the deal.

Read More

Deal could give Lilly full diabetes deck

Eli Lilly and Co.’s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.

Read More

Q&A: Derek Bang

Derek Bang, practice leader of health care advisory services at the Crowe Horwath accounting firm in Indianapolis, spent a week in March studying health care in the United Kingdom, especially its universal health care program. He was surprised by the “daily barrage of criticism” he heard about the National Health Service, but also found that the United Kingdom and United States face very similar issues when it comes to constraining growth in health care costs.

Read More

Lilly bumped up federal lobbying in third quarter

The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.

Read More

New doc lifts Community breast biz

Community Health Network wooed Dr. Robert J. Goulet Jr. to join its breast-surgery team from the Indiana University Simon Cancer Center. The move fits nicely with Community’s focus on breast-care services and the economics of health care.

Read More

Latest iPhone app: Baby EKG

Mobile medicine has arrived. Decatur County Memorial Hospital in Greensburg became the first hospital in Indiana to start using AirStrip OB, a patient-monitoring system that sends things like the heartbeat waves of patients directly to physicians’ iPhones, BlackBerrys or other mobile devices.

Read More

Lilly, other big drugmakers shut out by FDA in 2010

Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world’s largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.

Read More